Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling ActivitiesTargeting Initiation of Phase 1 ...
FDA IND clearance enables a phase 3 program evaluating TRIESENCE for postoperative ocular inflammation and pain following cataract surgery, aiming to broaden on-label use beyond current intraocular ...
Please provide your email address to receive an email when new articles are posted on . The acceptance paves the way for a pending phase 2b/3 clinical trial of COMP360 in PTSD. The manufacturer plans ...
Industry and FDA representatives have reached a general agreement on planned pre-submission facility meetings but have expressed different views about the specifics.
“Let it grow, let it blossom,” said Eric Clapton, and so the Food and Drug Administration expects of expanded access programs with the issuance of its guidance on “Expanded Access to Investigational ...
The FDA has faced an extraordinary convergence of political, scientific, legal, and operational pressures over the last year.
Cartography Biosciences, Inc., a biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has ...
Please provide your email address to receive an email when new articles are posted on . NOV05 will be evaluated in patients with noninfectious anterior uveitis. Novaliq plans to initiate a phase 2 ...
Understand the impact of IND delays on biotechnology companies and how they affect early-stage development and funding.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results